Ensoma
Daniel Leblanc brings to Ensoma extensive experience in pharmaceutical development and operations with an emphasis on novel drug delivery systems. Prior to Ensoma, Daniel spent more than seven years at Flexion Therapeutics, where he was responsible for the technical operations and product development organizations leading the commercialization of Flexion’s first product, Zilretta®, and was instrumental in the identification, in-licensing and technical development of FX201, a novel gene therapy for the treatment of osteoarthritis.
Ensoma
1 followers
Ensoma believes every person, no matter where they are, should have access to innovative technologies that are changing the way we treat disease. Harnessing the power of their Engenious™ vectors, their therapies can be delivered in a simple, single injection.